A detailed history of Citigroup Inc transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 23,145 shares of DSGN stock, worth $144,656. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,145
Previous 7,234 219.95%
Holding current value
$144,656
Previous $24,000 416.67%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.19 - $5.88 $50,756 - $93,556
15,911 Added 219.95%
23,145 $124,000
Q2 2024

Aug 12, 2024

BUY
$3.23 - $4.77 $2,923 - $4,316
905 Added 14.3%
7,234 $24,000
Q1 2024

May 10, 2024

BUY
$2.27 - $4.03 $3,436 - $6,101
1,514 Added 31.44%
6,329 $25,000
Q4 2023

Feb 09, 2024

BUY
$1.99 - $2.76 $8,041 - $11,153
4,041 Added 522.09%
4,815 $12,000
Q3 2023

Nov 09, 2023

SELL
$2.05 - $8.14 $20,381 - $80,927
-9,942 Reduced 92.78%
774 $1,000
Q2 2023

Aug 10, 2023

BUY
$4.99 - $7.64 $36,471 - $55,840
7,309 Added 214.53%
10,716 $67,000
Q1 2023

May 11, 2023

SELL
$5.5 - $9.77 $584,391 - $1.04 Million
-106,253 Reduced 96.89%
3,407 $19,000
Q4 2022

Feb 09, 2023

BUY
$7.86 - $17.2 $592,588 - $1.3 Million
75,393 Added 220.02%
109,660 $1.13 Million
Q3 2022

Nov 10, 2022

BUY
$14.09 - $25.57 $362,859 - $658,504
25,753 Added 302.48%
34,267 $573,000
Q2 2022

Aug 10, 2022

SELL
$9.91 - $17.33 $101,161 - $176,904
-10,208 Reduced 54.52%
8,514 $119,000
Q1 2022

May 12, 2022

SELL
$11.17 - $20.89 $105,858 - $197,974
-9,477 Reduced 33.61%
18,722 $302,000
Q4 2021

Feb 10, 2022

BUY
$13.64 - $21.41 $46,253 - $72,601
3,391 Added 13.67%
28,199 $604,000
Q3 2021

Nov 10, 2021

BUY
$13.99 - $20.03 $347,063 - $496,904
24,808 New
24,808 $364,000

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.